Category: Diseases, Syndromes and Conditions

Africa has 94% of All Malaria Cases

On November 30, the World Health Organization released this year’s World Malaria Report. Providing an up-to-date overview of the current global malaria disease burden, it also tracks investment, innovation and research against malaria.

Globally, malaria deaths have steadily declined over the years 2000–2019, from 736 000 in 2000 to 409 000 in 2019. The percentage of total malaria deaths that were children under 5 years of age was 84% in 2000 and 67% in 2019.

Six African countries accounted for 51% of global cases, with Nigeria (27%) contributing more than the other five countries combined. Partly this is due to its large relative population size compared to the rest of Africa, having over 200 million citizens.

Elsewhere, great progress is being made, The largest reduction in cases in the WHO South-East Asia Region was seen by India, from about 20 million cases in 2000 down to approximately 5.6 million in 2019.  Sri Lanka has been certified malaria free since 2015.

Source: Outbreak News Today

A Common Antibiotic Shows Promise for Zika Protection

A huge search through known drug compounds showed that a common antibiotic has been shown to be effective against Zika in vitro. Zika, which causes foetal microcephaly, preferentially attacks brain stem cells. 

In order to find a compound that confers Zika protection, the researchers searched for drugs that prevent virus reproduction by blocking the activity of a protein called NS2B-NS3 Zika virus protease. This protease acts to assemble the components of new Zika viruses from protein produced by the virus’ RNA injection into a cell.

“Proteases act like scissors. Blocking protease activity is an effective strategy for counteracting many viruses,” said study leader Rachel Abrams, PhD. “We wanted to look as far and wide as possible for drugs that could prevent the protease from snipping the Zika virus polyprotein into its active pieces.”

To find out which compounds blocked the protease, hundreds of assays were conducted against three different libraries.

An initial screen of 2 000 compounds showed that common tetracycline-based antibiotic drugs, such as methacycline were able to block the protease.

A larger screen of 10 000 compounds found potential candidates in an investigational anti-inflammatory medicine, MK-591, and a failed anti-Alzheimer’s disease drug, JNJ-404.  

Finally, 130 000 compounds were screened virtually, with machine learning being used to investigate what made a good candidate.

The candidate compounds were shown to reduce Zika infections of brain stem cells in vitro.

As methacycline is known to cross the placental barrier, this emerged as a promising candidate to treat pregnant women infected with the virus. However in mouse models, treatment with methacycline only partially protected the brains of newborn mice.

“These results suggest that tetracycline-based antibiotics may at least be effective at preventing the neurological problems associated with Zika virus infections,” said Dr Abrams. “Given that they are widely used, we hope that we can rapidly test their potential in clinical trials.”

Source: News-Medical.Net

Gut Microbiome is Linked to Pulmonary Disease

A link has been shown between the gut microbiome and chronic obstructive pulmonary disease (COPD), a lung disease with an often poor prognosis.

Senior author Prof Phil Hansbro, Director of the Centenary University of Technology Sydney Centre for Inflammation, said, “It’s already known that the lung microbiome is a contributing factor in COPD. We wanted to see if the gut environment was also somehow involved–to determine whether the gut could act as a reliable indicator of COPD or if it was connected in some way to the development of the disease.”

Stool samples of COPD patients showed elevated levels of the bacteria Streptococcus and Lachnospiraceae. Additionally a unique metabolite signature was identified in individuals with COPD, created by the chemical by-products of the metabolic process.

First author Dr Kate Bowerman from the University of Queensland said, “Our research indicates that the gut of COPD patients is notably different from healthy individuals. This suggests that stool sampling and analysis could be used to non-invasively diagnose and monitor for COPD,” she said.
“The ‘gut-lung axis’ describes the common immune system of the lung and gastrointestinal tract. This means that activity in the gut can impact activity in the lung. Our COPD findings suggest that the gut microbiome should now also be considered when looking for new therapeutic targets to help treat lung disease,” Prof Hansbro said.

Source: Medical Xpress

Re-emergence of Scarlet fever

Scarlet fever has made a re-emergence in recent years due to acquiring a toxin that allows them to better colonise their hosts:

“These supercharged bacterial clones have been causing our modern scarlet fever outbreaks.

“The research team then removed the toxin genes from the clones causing scarlet fever, and these modified ‘knock-out’ clones were found to be less able to colonize in an animal model of infection.”

For the time being, scarlet fever outbreaks have been dampened, largely due to public health policy measures introduced to control COVID-19.

“This year COVID-19 social distancing has kept scarlet fever outbreaks in check for now,” Professor Walker said.

“And the disease’s main target—children—have been at school less and also spending far less time in other large groups.

“But when social distancing eventually is relaxed, scarlet fever is likely to come back.

“We need to continue this research to improve diagnosis and to better manage these epidemics.

“Just like COVID-19, ultimately a vaccine will be critical for eradicating scarlet fever—one of history’s most pervasive and deadly childhood diseases.”

Source: Medical Express

DRC is Ebola-free Once Again After 11th Outbreak Ends

The 11th outbreak of Ebola in the Democratic Republic of Congo has officially come to an end, and the country has been declared Ebola-free once again.

The outbreak which had spread along the many water bodies of Équateur province, had started just before the end of another deadly outbreak elsewhere in the country which had claimed 2280 lives. This marks the first time in nearly three years that the DRC has been Ebola-free. Logistical challenges in the geographically remote Équateur province hampered efforts to control the latest outbreak.

Experts believe that international involvement was key to bringing the situation under control. The WHO also noted that “women leaders [who] were often at the forefront of the response, empowering other women with information”.

The Secretary-General of DRC’s Red Cross, Jacques Katshishi, said the country needs continued support from the international community. He said, “Bringing Ebola to zero is a huge achievement, but now we are faced with our next challenge: keeping it there. Our teams within the DRC Red Cross are facing Covid-19 within a complex humanitarian and security environment. This is not a moment to be complacent: the world cannot afford a resurgence of Ebola in DR Congo. The time to prepare is now.”

Source: The Guardian

Human Transmission in 2019 Outbreak of Deadly Chapare Virus

In 2019, five people were infected and three died near the Bolivian capital La Paz by the Chapare virus. US Centers for Disease Control and Prevention (CDC) researchers detailed new clues to the mysterious disease that have recently been uncovered.

The Chapare virus is an arenavirus, like the deadly Lassa virus which, in West Africa, causes thousands of deaths every year. Similar to the Ebola virus, arenaviruses can produce a haemorrhagic fever, causing multiple organ damage. 

The researchers identified human transmission from patients to healthcare workers, and believe that blood, semen and other bodily fluids can transmit the disease.
Caitlin Cossaboom, DVM, PhD, MPH, an epidemiologist with the CDC’s Division of High-Consequence Pathogens and Pathology, said, “Our work confirmed that a young medical resident, an ambulance medic and a gastroenterologist all contracted the virus after encounters with infected patients–and two of these healthcare workers later died. We now believe many bodily fluids can potentially carry the virus.”

Viral DNA was found in the semen of one the survivors, raising the prospect of sexual transmission. Viral DNA was also found in rodents in the area, although the researchers cautioned that it did not necessarily represent a source. 

“The genome sequence of the RNA we isolated in rodent specimens matches quite well with what we have seen in human cases,” Cassaboom said.

By pooling resources, researchers were able to make rapid headway in identifying the disease. Gene sequencing technology quickly confirmed the virus as a match for the original 2004 outbreak.

Source: Eureka Alert

Major Cardiovascular Events Cut by Use of Polypills

Results presented in a late-breaking clinical trial presentation at the American Heart Association’s Scientific Sessions 2020 reported that large randomised trial demonstrated that a simple polypill (containing cholesterol and blood pressure control medication) could significantly reduce cardiovascular risk.

In the International Polycap Study (TIPS)-3, 5700 participants in 9 countries were given either the polypill, aspirin, the polypill plus aspirin or Vitamin D and monitored for five years for major cardiovascular events.

The polypill contained atenolol 100mg, ramipril 10mg, hydrochlorothiazide 25 mg, and simvastatin 40 mg.

The combination of polypill and aspirin reduced cardiovascular events by 31%, whilst aspirin alone had a 14% reduction and 21% with polypill alone.

Salim Yusuf, MD, BS, D Phil, co-author of the study said, “Aspirin should be prescribed with a polypill in primary prevention for patients at intermediate risk of heart disease. Our study results provide important data regarding the role of the polypill in preventing the development of heart disease.”

Source: News-Medical.Net

Weight Link to COVID Risk Emphasised by CDC

The Centers for Disease Control and Prevention (CDC) in the US has included in its coronavirus risk warning people who are considered overweight (a BMI of 25 to 29.9, obese is above 30).

Dr Donald Hensrud, director of the Mayo Clinic Healthy Living Program, explained that obesity already is associated with several complications – diabetes, high blood pressure, dyslipidaemia and cardiovascular disease.

Dr Hensrud said, “Now COVID-19 comes along, and we’ve got all the issues we had before plus some additional ones. Obesity is associated with low-grade inflammation and an effect on our immune system. This affects our susceptibility to COVID-19. People who are obese are more likely to develop COVID-19 and complications from it, including dying, than people who aren’t obese. In addition, people with diabetes and some of the other complications from obesity are also at increased risk. So obesity and its complications independently take the risks of COVID-19 and elevate them significantly.”

Dr Hensrud said that he noted patients of his had put on weight during lockdown due to comfort eating and staying at home without any exercise. In order to reduce their risk, people should resolve to eat a healthy diet and engage in exercise, although he cautioned that losing more than 10% body weight in six months can impact the immune system.

Source: Medical Xpress

Promising Drug May Worsen Instead of Treat Multiple Sclerosis

A drug, TEPP-46,  that is being assessed to treat multiple sclerosis (MS) may in fact be worsening the progression of the disease, wrote University of Virginia on the Medical Xpress website.

MS is a debilitating disease which affects over one million people in America, in which the immune system attacks the myelin sheath, creating a range of effects in sufferers, from muscle spasms to numbness.

Presently available drugs to treat MS often have unwanted side effects, such as weakening the immune system. Originally developed to fight cancer, TEPP-46 is small-molecule drug that targets the changes in cellular metabolism that occur in both cancer and MS. However, the drug has been shown to produce off-target effects. In the mouse model used by the researchers, the inflammation was directed away from the spinal cord and into the brain. The researchers believed that this was the result of the drug harmfully changing T cells, but could not explain why. 

“It was not at all what we expected,” said MS researcher Alban Gaultier, PhD, of University of Virginia. “The take-home message is that we should be very careful and do more fundamental research before we propose to take this to clinical trials.”

Vaping May Increase Respiratory Disease Risk

Research has increasingly been focused on the health effects of vaping, usually touted as a way to quit combustible smoking, and evidence is accumulating for their risks.

Research by Boston University School of Public Health and School of Medicine has revealed that, far from being harmless, vaping may in fact raise the risk for a number of respiratory diseases by 21% for former e-cigarette users and 43% for current users.

Corresponding author Dr Andrew Stokes, assistant professor of global health at Boston University said, “This provides some of the very first longitudinal evidence on the harms associated with e-cigarette products.

“In recent years we have seen dramatic increase in e-cigarette use among youth and young adults which threatens to reverse decades of hard-fought gains,” Stokes said. “This new evidence also suggests that we may see an increase in respiratory disease as youth and young adults age into midlife, including asthma, COPD, and other respiratory conditions.”

Previous research has largely focused on in vitro studies, or short-term studies with human participants. The study used data from 21 618 participants from the nationally representative Population Assessment of Tobacco and Health (PATH) survey. To isolate the effect of e-cigarettes, the researchers adjusted for any form of combustible smoking use, including second-hand smoking.

“With a longitudinal study design and extensive sensitivity analyses, the study adds to a growing body of evidence indicating long-term health risks of e-cigarette use to the respiratory system,” said study lead author Wubin Xie, a postdoctoral associate at Boston University.

Source: Medical Xpress